Lineage Cell Therapeutics, Inc.
A clinical-stage biotechnology company developing "off-the-shelf" cell therapies for serious conditions, including spinal cord injuries and age-related macular degeneration. It began in 1990 as BioTime before rebranding in 2019 to its current name, which reflects how its platform steers stem cells along specific "lineages" to become particular cell types. Its programs include OPC1 for spinal cord repair and OpRegen for the eye disease dry AMD.
Common Share Purchase Warrants expiring October 1, 2018, exercise price .55
Bought 14.63M
Bought 40.0K
Granted 102.7K · Bought 65.0K
Bought 96.2K
Granted 20.0K · Bought 15.0K
Bought 25.5K
Bought 10.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Bradsher Neal C +2 co-filersDirector, 10% owner, 10% owner · 4 transactions | +42.8% | 99.21Mas of Jan 2025 | — | 14.63M | — |
| Mulroy Michael H.Director · 1 transaction | +15.5% | 298.6Kas of Nov 2024 | — | 40.0K | — |
| Culley Brian MPresident and CEO, Director · 11 transactions | +102.2% | 255.5K | 102.7K | 65.0K | — |
| Bailey Don MDirector · 1 transaction | — | 158.8Kas of Feb 2024 | — | 96.2K | — |
| Samuel George A. IIIGeneral Counsel and Secretary · 9 transactions | +763.3% | 31.1K | 20.0K | 15.0K | — |
| Howe Jill AnnChief Financial Officer · 2 transactions | — | 25.5Kas of Nov 2024 | — | 25.5K | — |
| Jayasuriya AnulaDirector · 1 transaction | — | 10.0Kas of Dec 2023 | — | 10.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +14.88M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.